ArticleAging cell2026
Mesenchymal Stem Cell-Derived Exosomes Improve Aging-Related Changes in Liver Lipid Metabolism by Enhancing Autophagy.
Article in Aging cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Health problems associated with aging have become increasingly severe in recent years. For example, hepatic lipid metabolism declines as the body ages, leading to lipid metabolic disorders. Although exosomes have been explored for treating metabolic diseases, there is currently a paucity of research regarding aging-related changes in hepatic lipid metabolism. Herein, we cultured human umbilical cord mesenchymal stem cells (HucMSCs), from which we extracted HucMSC-derived exosomes (HucMDEs). We then established a natural aging mouse model in vivo and a palmitic acid-induced AML12 cell model in vitro; HucMDEs were subsequently used as an intervention. Western blot analysis and quantitative real-time PCR were used to investigate changes in liver lipid metabolism and senescence-related markers in vivo and in vitro. Our results revealed that the HucMDE-injected mice showed reduced body weights, increased insulin sensitivity, decreased hepatic lipid deposition, reduced senescence, and augmented autophagy levels compared with the aged group of mice. The in vitro results were consistent with the in vivo results. When autophagy-related genes were silenced in AML12 cells via small interfering RNAs, or when cells were treated with the autophagy inhibitor 3-methyladenine or the lysosomal inhibitor bafilomycin A1, HucMDEs were able to reverse the reduction in hepatocyte autophagy levels. In this study, we demonstrated that HucMDEs improved hepatic lipid metabolism and attenuated cellular senescence by enhancing autophagy. We expect that these findings will provide novel potential therapeutic targets for the treatment of hepatic lipid metabolism disorders during aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.